Summary

The oligonucleotide synthesis market is projected to reach USD 19.7 billion by 2029 from USD 8.8 billion in 2024, at a CAGR of 17.5% during the forecast period. The synthesized oligonucleotide market is projected to reach USD 4.9 billion in 2029 from USD 2.2 billion in 2024, growing at a CAGR of 17.0% during the forecast period. The growth of this market is driven by several factors such as the increasing use of synthesized oligonucleotides such as primers and probes for various research and diagnostic applications. Technological advancements in the field of oligonucleotide synthesis further contribute to the growth of the market.

“The oligonucleotide synthesis market growth for synthesized oligonucleotides can be attributed to the growing research focused on the development of novel oligonucleotide-based drugs and their wide applications in diagnostic procedures.”
The oligonucleotide synthesis market, based on synthesized oligonucelotides (part of product segmentation), is further segmented into primer, probes, DNA Oligos, RNA Oligos, Other synthesized oigonucelotides. Synthesized oligonucelotides have a wide application in research for novel drug development and are mainly used in PCR and sequencing. Additionlly, diagnostic procedures used for detection of genetic disorders, companion diagnostics are also few of the major application areas for synthesized oligonucelotides.
“The primers segment will grow at the highest rate in the synthesized oligos market, by product.”
By Product, synthesized oligonucelotide maket is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos including BNA & LNA oligos. Primers are expected to grow at the highest rate during the forecasted period owing to the extensive use of primers in a wide range of applications such as PCR, sequencing, gene synthesis and cloning. Primers allow aplification of target gene sequences for gene expression studies, molecular diagnostics and genetic analysis.
“By therapeutic application, the neurological disease segment accounted for the largest share of the oligonucleotide synthesis market in 2023.”
The therapeutic application segment is segmented by disease type into neurological, rare and other diseases. In 2023, neurological disease segment accounted for the largest share of this segment as major companies are focusing on the development of oligo-based drugs for the treatment of neurological diseases such as DMD and SMA. Oligo based drugs that are used as therapies for these disorders have most FDA approvals.
“North American region is expected to register a highest CAGR in the oligonucleotide synthesis market.”
The market for oligonucleotide synthesis in North America is estimated to grow at the highest rate during the forecast period. Ongoing investments and funding provided by various government bodies, biotechnology and pharmaceutical companies to develop oligonucelotide based therapies for various rare and neurological disease, presence of strong venture capital ecosystem, growing awareness and early adoption of novel and alternate therapies in this region are few factors that support thr growth of this regional market. North America also has the established pharmceutical manufacturing infrastructure and the presence of the promnient players of the oligonucleotide synthesis market such as Danaher Corporation and Thermo Fisher among other which futher supports the leadership position of this region.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side - 30%
• By Designation: Managers- 45%, CXOs, and Director level - 30%, and Executives - 25%
• By Region: North America -35%, Europe - 25%, Asia-Pacific -15%, Latin America -10%, Middle East- 10%, Africa- 5%
List of Companies Profiled in the Report Offering Products For Research and Diagnostic Applications:
• Danaher Corporation (US)
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Eurofins Scientific (Luxembourg)
• LGC Limited (UK)
• Agilent Technologies, Inc. (US)
• Kaneka Corporation (Japan)
• Maravai Lifesciences holdings, Inc. (US)
• Azenta, Inc. (US)
• Twist Bioscience Corporation (US)
• Genscript Biotech Corporation (US)
List of Companies Profiled in the Report Offering Products For Therapeutic Applications:
• Biogen Inc. (US)
• Alnylam Pharmaceuticals, Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• Astrazeneca (UK)
• Astellas Pharma Inc. (Japan)
• Jazz Pharmaceuticals Plc (Ireland)
• Nippon Shinyaku, Co. Ltd. (Japan)
• Ionis Pharmaceuticals, Inc. (US)
• Novartis AG (Switzerland)
Note: Above list is inexhaustive

Research Coverage:
This report provides a detailed picture of the oligonucleotide synthesis market. It aims to estimate the market’s size and future growth potential across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, key market strategies, funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oligonucleotide synthesis market.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (e.g., Increasing use of synthesized oligos in therapeutic and diagnostic applications, Technological advancements), restraints (e.g., complexities associated with oligonucleotide-based drugs), opportunities (e.g., increasing pharma R&D investments in emerging economies), and challenges (e.g., lack of standard regulations) are influencing the growth of the oligonucleotide synthesis market.
• Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the oligonucleotide synthesis market across varied regions.
• Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market.
• Pipeline Analysis: Comprehensive information about products under clinical trials.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), among others offering products for research & diagnostic applications and Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US) among others offering products for therapeutic applications.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 63
1.1 STUDY OBJECTIVES 63
1.2 MARKET DEFINITION 63
1.3 INCLUSIONS & EXCLUSIONS 64
1.4 MARKET SCOPE 65
FIGURE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION 65
FIGURE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: REGIONAL SEGMENTATION 66
1.4.1 YEARS CONSIDERED 66
1.4.2 CURRENCY CONSIDERED 67
1.5 RESEARCH LIMITATIONS 67
1.6 STAKEHOLDERS 67
1.7 SUMMARY OF CHANGES 67
1.7.1 RECESSION IMPACT: OLIGONUCLEOTIDE SYNTHESIS MARKET 68
2 RESEARCH METHODOLOGY 69
2.1 RESEARCH DATA 69
FIGURE 3 RESEARCH DESIGN 69
2.1.1 SECONDARY DATA 70
2.1.2 PRIMARY DATA 71
FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 71
2.2 MARKET SIZE ESTIMATION 72
FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023 72
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1A (REVENUE SHARE ANALYSIS FOR RESEARCH & DIAGNOSTIC APPLICATIONS), 2023 73
FIGURE 7 MARKET SIZE ESTIMATION: APPROACH 1B (REVENUE SHARE ANALYSIS FOR THERAPEUTIC APPLICATIONS), 2023 73
FIGURE 8 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION (RESEARCH AND DIAGNOSTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2023 74
FIGURE 9 ILLUSTRATIVE EXAMPLE OF BIOGEN INC. (THERAPEUTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2023 74
FIGURE 10 MARKET VALIDATION FROM PRIMARY EXPERTS 76
2.2.1 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL 76
FIGURE 11 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 76
2.3 MARKET GROWTH FORECAST 77
FIGURE 12 CAGR PROJECTIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET, 2024–2029 78
FIGURE 13 CAGR PROJECTIONS: OLIGONUCLEOTIDE-BASED DRUGS MARKET (THERAPEUTIC APPLICATIONS), 2024–2029 78
FIGURE 14 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN OLIGONUCLEOTIDE SYNTHESIS MARKET 79

2.4 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION 79
2.5 MARKET BREAKDOWN & DATA TRIANGULATION 80
FIGURE 15 DATA TRIANGULATION METHODOLOGY 80
2.6 STUDY ASSUMPTIONS 81
2.7 RISK ANALYSIS 81
2.8 IMPACT OF RECESSION ON OLIGONUCLEOTIDE SYNTHESIS MARKET 81
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 81
TABLE 2 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION) 82
3 EXECUTIVE SUMMARY 83
FIGURE 16 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 83
FIGURE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 84
FIGURE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2024−2029 (USD MILLION) 84
FIGURE 19 GEOGRAPHICAL SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET 85
4 PREMIUM INSIGHTS 86
4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW 86
FIGURE 20 INCREASING USE OF SYNTHESIZED OLIGOS TO DRIVE MARKET GROWTH 86
4.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION AND COUNTRY (2023) 87
FIGURE 21 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023 87
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY PRODUCT, 2024 VS. 2029 87
FIGURE 22 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2029 87
4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2023 88
FIGURE 23 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 88
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 88
FIGURE 24 NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 88
5 MARKET OVERVIEW 89
5.1 INTRODUCTION 89
5.2 MARKET DYNAMICS 89
FIGURE 25 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 89
TABLE 3 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS 90
5.2.1 DRIVERS 90
5.2.1.1 Increasing use of synthesized oligos in therapeutic and diagnostic applications 90
TABLE 4 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016-2023) 91
5.2.1.2 Technological advancements 92
5.2.1.3 Growing government investments in life science research and synthetic biology 93
5.2.1.4 Growing focus on precision/personalized medicine 94
5.2.2 RESTRAINTS 94
5.2.2.1 Complexities associated with therapeutic oligonucleotides 94
5.2.3 OPPORTUNITIES 94
5.2.3.1 Increasing R&D investments by key players in emerging economies 94
5.2.4 CHALLENGES 95
5.2.4.1 Lack of standard regulations 95
5.2.4.2 Delivery of oligonucleotide drugs to specific targets 96
5.3 MARKET TRENDS 96
5.3.1 FOCUS ON DEVELOPING NEW DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS 96
5.3.2 FOCUS ON DEVELOPING NEW TECHNOLOGIES FOR SUSTAINABLE AND LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES 97
5.3.3 FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION 98
TABLE 5 LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 98
5.3.4 GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL AND RARE DISEASES 98
TABLE 6 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS 99
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 99
FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR OLIGONUCLEOTIDE MANUFACTURERS 99
5.5 SUPPLY CHAIN ANALYSIS 100
FIGURE 27 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES 101
5.6 VALUE CHAIN ANALYSIS 101
FIGURE 28 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 102
5.7 ECOSYSTEM ANALYSIS 103
FIGURE 29 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET 103
5.7.1 ROLE IN ECOSYSTEM 103
5.8 TECHNOLOGY ANALYSIS 104
5.8.1 KEY TECHNOLOGIES 104
5.8.1.1 Solid-phase synthesis 104
5.8.1.2 Liquid-phase synthesis 105
5.8.1.3 Enzymatic oligo synthesis 105
5.8.2 COMPLEMENTARY TECHNOLOGIES 105
5.8.2.1 Polymerase chain reaction (PCR) 105
5.8.2.2 Next-generation sequencing 106
5.8.3 ADJACENT TECHNOLOGIES 106
5.8.3.1 Clustered regularly interspaced short palindromic repeats (CRISPR) 106

5.9 PRICING ANALYSIS 106
TABLE 7 INDICATIVE PRICING OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS 106
TABLE 8 AVERAGE SELLING PRICE FOR MAJOR OLIGONUCLEOTIDE-BASED DRUGS 108
5.10 PATENT ANALYSIS 108
5.10.1 PATENTS FILED, BY DOCUMENT TYPE, 2012–2023 108
FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2012–DECEMBER 2023) 109
TABLE 9 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 109
5.11 PIPELINE ANALYSIS 111
FIGURE 31 NUMBER OF ONGOING CLINICAL TRIALS FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COMPANY 111
FIGURE 32 NUMBER OF ESTIMATED LAUNCHES, 2024–2028 112
TABLE 10 OLIGONUCLEOTIDE-BASED DRUGS IN CLINICAL PIPELINE 112
5.12 TRADE ANALYSIS 117
5.13 KEY CONFERENCES & EVENTS IN 2024–2025 117
TABLE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS 117
5.14 REGULATORY LANDSCAPE 118
5.14.1 REGULATORY ANALYSIS 118
5.14.2 REGULATORY BODIES 119
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 120
TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 120
TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 121
5.15 PORTER’S FIVE FORCES ANALYSIS 121
TABLE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 121
5.15.1 DEGREE OF COMPETITION 121
5.15.2 BARGAINING POWER OF SUPPLIERS 122
5.15.3 BARGAINING POWER OF BUYERS 122
5.15.4 THREAT OF SUBSTITUTES 122
5.15.5 THREAT OF NEW ENTRANTS 122
5.16 KEY STAKEHOLDERS & BUYING CRITERIA 123
5.16.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 123
5.16.2 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: HOSPITALS 123

5.17 KEY BUYING CRITERIA 124
5.17.1 BUYING CRITERIA OF END USERS FOR SYNTHESIZED OLIGONUCLEOTIDE PRODUCTS 124
5.17.2 BUYING CRITERIA FOR SYNTHESIZED OLIGONUCLEOTIDES, BY END USER 124
5.17.3 BUYING CRITERIA OF HOSPITALS FOR OLIGONUCLEOTIDE THERAPEUTIC PRODUCTS 125
5.17.4 BUYING CRITERIA FOR OLIGONUCLEOTIDE-BASED THERAPEUTIC PRODUCTS BY HOSPITALS 126
5.18 CASE STUDY ANALYSIS 127
5.18.1 CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT 127
5.18.2 CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING 127
5.18.3 CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA 127
5.19 INVESTMENT/FUNDING SCENARIO 128
6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT 129
6.1 INTRODUCTION 130
TABLE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 130
6.2 OLIGONUCLEOTIDE-BASED DRUGS 130
TABLE 19 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION) 131
TABLE 20 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 21 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 22 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 23 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 24 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 25 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 26 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT, 2022–2029 (NUMBER OF VIALS) 134
6.2.1 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE 134
TABLE 27 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 135
6.2.1.1 Antisense oligonucleotide-based drugs 135
6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth 135
TABLE 28 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS 136
TABLE 29 ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION) 136
TABLE 30 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 31 EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 32 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 33 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 34 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 35 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
6.2.1.2 siRNA oligonucleotide-based drugs 139
6.2.1.2.1 Large pipeline of products to favor market growth 139
TABLE 36 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS 140
TABLE 37 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION) 140
TABLE 38 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 39 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 40 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 41 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 42 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 43 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 142
6.2.1.3 Other oligonucleotide-based drugs 143
TABLE 44 APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS 143
TABLE 45 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION) 144
TABLE 46 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 47 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 48 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 49 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 50 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 51 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 146

6.3 SYNTHESIZED OLIGONUCLEOTIDES 146
TABLE 52 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 147
TABLE 53 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 54 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 55 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 56 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 57 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 58 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 59 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 149
6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT 149
6.3.1.1 Primers 149
6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth 149
TABLE 60 OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2022–2029 (USD MILLION) 150
TABLE 61 NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 62 EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 63 ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 64 LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 65 MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 66 GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 152
6.3.1.2 Probes 153
6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth 153
TABLE 67 OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2022–2029 (USD MILLION) 154
TABLE 68 NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 69 EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 70 ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 71 LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 72 MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 73 GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 156
6.3.1.3 DNA oligonucleotides 156
6.3.1.3.1 Diverse usage of DNA oligos to support market growth 156
TABLE 74 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 157
TABLE 75 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 76 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 77 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 78 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 79 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 80 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 159
6.3.1.4 RNA oligonucleotides 159
6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth 159
TABLE 81 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 160
TABLE 82 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 83 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 84 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 85 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 86 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 87 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 162
6.3.1.5 Other synthesized oligonucleotides 162
TABLE 88 OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 163
TABLE 89 NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 90 EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 91 ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 92 LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 93 MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 94 GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 165
6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE 165
TABLE 95 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 165
6.3.2.1 Custom oligonucleotides 165
6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth 165
TABLE 96 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 166
TABLE 97 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 166
TABLE 98 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 167
TABLE 99 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 167
TABLE 100 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 101 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 102 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 168
6.3.2.2 Predesigned oligonucleotides 169
6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption 169
TABLE 103 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 169
TABLE 104 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 105 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 106 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 107 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 108 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 109 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
6.4 REAGENTS & CONSUMABLES 172
6.4.1 GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS 172
TABLE 110 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION) 172
TABLE 111 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 112 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 113 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 114 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 115 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 116 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
6.5 EQUIPMENT 175
6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET 175
TABLE 117 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION) 175
TABLE 118 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 119 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 120 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 121 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 122 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 123 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 178
7.1 INTRODUCTION 179
TABLE 124 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 179
7.2 THERAPEUTIC APPLICATIONS 179
TABLE 125 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 180
TABLE 126 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 127 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 128 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 129 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 130 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 131 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 182
7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE 183
TABLE 132 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 183
7.2.1.1 Neurological disorders 183
7.2.1.1.1 Growing research on use of oligonucleotide-based drugs for treatment of DMD and SMA to promote market growth 183
TABLE 133 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION) 184
TABLE 134 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 135 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 136 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 137 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 138 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 139 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 186
7.2.1.2 Rare diseases 187
7.2.1.2.1 High specificity and efficacy of oligo-based drugs against rare diseases to support growth 187
TABLE 140 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2022–2029 (USD MILLION) 187
TABLE 141 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 142 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 143 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 144 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 145 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 146 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 189
7.2.1.3 Other diseases 190
TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION) 190
TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 152 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 153 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 192
7.3 RESEARCH APPLICATIONS 193
TABLE 154 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 155 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 193
TABLE 156 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 157 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 158 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 195
TABLE 159 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 195
TABLE 160 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 195
TABLE 161 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 196
7.3.1 PCR 196
7.3.1.1 Increasing use of PCR in molecular biology research to drive market growth 196
TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2022–2029 (USD MILLION) 197
TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 197
TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 197
TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 167 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 168 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 199
7.3.2 SEQUENCING 199
7.3.2.1 Advancements in sequencing technologies and low cost of DNA sequencing to boost growth 199
TABLE 169 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2022–2029 (USD MILLION) 200
TABLE 170 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 171 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 201
TABLE 173 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 201
TABLE 174 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 201
TABLE 175 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 202
7.3.3 OTHER RESEARCH APPLICATIONS 202
TABLE 176 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 203
TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 178 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 179 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 204
TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 204
TABLE 181 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 204
TABLE 182 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 205
7.4 DIAGNOSTIC APPLICATIONS 205
7.4.1 INCREASING DEMAND FOR RELIABLE, SPECIFIC, AND FAST METHODS FOR DETECTION OF VARIOUS DISEASES TO SUPPORT GROWTH 205
TABLE 183 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 206
TABLE 184 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 185 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 186 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 207
TABLE 187 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 207
TABLE 188 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 207
TABLE 189 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 208
8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 209
8.1 INTRODUCTION 210
TABLE 190 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 210
8.2 HOSPITALS 210
8.2.1 INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET GROWTH 210
TABLE 191 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION) 211
TABLE 192 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 193 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 194 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 195 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 213
TABLE 196 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 213
TABLE 197 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 213
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 214
8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO DRIVE GROWTH 214
TABLE 198 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 215
TABLE 199 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 215
TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 215
TABLE 201 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 216
TABLE 202 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 216
TABLE 203 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 216
TABLE 204 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 217
8.4 DIAGNOSTIC LABORATORIES 217
8.4.1 GROWING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL GROWTH 217
TABLE 205 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 218
TABLE 206 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 218
TABLE 207 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 218
TABLE 208 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 210 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 211 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 220